EPISTOP
Long-term, prospective study evaluating clinical and molecular biomarkers of epileptogenesis in a genetic model of epilepsy – tuberous sclerosis complex
| Coordinatore | INSTYTUT POMNIK CENTRUM ZDROWIA DZIECKA
Organization address
address: Aleja Dzieci Polskich 20 contact info |
| Nazionalità Coordinatore | Poland [PL] |
| Sito del progetto | http://www.epistop.eu |
| Totale costo | 13˙019˙934 € |
| EC contributo | 9˙451˙675 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2013-INNOVATION-1 |
| Funding Scheme | CP-IP |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-11-01 - 2018-10-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
INSTYTUT POMNIK CENTRUM ZDROWIA DZIECKA
Organization address
address: Aleja Dzieci Polskich 20 contact info |
PL (WARSZAWA) | coordinator | 1˙561˙770.00 |
| 2 |
ServiceXS BV
Organization address
address: Plesmanlaan 1.d contact info |
NL (Leiden) | participant | 819˙000.00 |
| 3 |
INTERNATIONAL INSTITUTE OF MOLECULAR AND CELL BIOLOGY
Organization address
address: ks. Trojdena 4 contact info |
PL (Warsaw) | participant | 774˙818.00 |
| 4 |
PROTEOME FACTORY AG
Organization address
address: MAGNUSSTRASSE 11 contact info |
DE (BERLIN) | participant | 758˙800.00 |
| 5 |
Academisch Medisch Centrum bij de Universiteit van Amsterdam
Organization address
address: MEIBERGDREEF 9 contact info |
NL (AMSTERDAM) | participant | 727˙275.00 |
| 6 |
The Brigham and Women's Hospital, Inc.
Organization address
address: Francis Street 75 contact info |
US (Boston) | participant | 653˙053.00 |
| 7 |
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Organization address
address: HEIDELBERGLAAN 100 contact info |
NL (UTRECHT) | participant | 635˙537.40 |
| 8 |
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Organization address
address: Chariteplatz 1 contact info |
DE (BERLIN) | participant | 575˙752.80 |
| 9 |
KATHOLIEKE UNIVERSITEIT LEUVEN
Organization address
address: Oude Markt 13 contact info |
BE (LEUVEN) | participant | 566˙898.00 |
| 10 |
UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATA
Organization address
address: VIA ORAZIO RAIMONDO 18 contact info |
IT (ROMA) | participant | 560˙303.00 |
| 11 |
MEDIZINISCHE UNIVERSITAET WIEN
Organization address
address: SPITALGASSE 23 contact info |
AT (WIEN) | participant | 542˙028.50 |
| 12 |
VRIJE UNIVERSITEIT BRUSSEL
Organization address
address: PLEINLAAN 2 contact info |
BE (BRUSSEL) | participant | 452˙015.00 |
| 13 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 403˙112.00 |
| 14 |
FAKULTNI NEMOCNICE V MOTOLE
Organization address
address: V UVALU 84 contact info |
CZ (PRAHA 5) | participant | 290˙512.30 |
| 15 |
ARS CONSULTING SRL
Organization address
address: VIA SEBASTIANO GRANDIS 1 contact info |
IT (ROMA) | participant | 130˙800.00 |
| 16 |
CHILDREN'S HEALTH QUEENSLAND HOSPITAL AND HEALTH SERVICE
Organization address
address: Lady Cilento Childrens Hospital, 501 Stanley Street contact info |
AU (Brisbane) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
Despite a great progress in the management of epilepsy, still one third of patients is refractory to available medications. The incidence of epilepsy is highest in infancy and 50% of children experience epilepsy-related comorbidities, such as developmental delay and autism. The development of epilepsy (epileptogenesis), extensively studied in animals, is barely studied in humans, as patients usually present AFTER the seizure onset. EPISTOP is the first prospective study of epileptogenesis in humans, beginning BEFORE seizures and continuing through age 2 years, permitting detailed analysis of the onset, drug-resistance, and comorbidities of epilepsy. To maximize information derived from the study we have chosen homogenous group of patients with prenatal or early infantile diagnosis of Tuberous Sclerosis Complex (TSC). A clinical randomized study of pre-seizure treatment in TSC infants is a part of the project. The aim of EPISTOP is to examine the risk factors and biomarkers of epilepsy and to identify possible new therapeutic targets to block or otherwise modify epileptogenesis in humans. Biomarker analysis will be performed by a multidisciplinary, systematic approach in three clinical settings: 1/ prospective study of epilepsy development in infants with TSC, including analysis of clinical, neuroimaging, and molecular, blood-derived biomarkers at predefined time points: before the onset of seizures, at the onset of epileptiform discharges on EEG, at seizure onset and at the age of 24 months 2/ prospective study of blood-based biomarkers in infants with TSC treated with antiepileptic drugs prior to seizure onset in comparison to children treated only after clinical seizures appearance. 3/ analysis of biomarkers of epileptogenesis and drug-resistant epilepsy in brain specimens obtained from TSC patients who have had epilepsy surgery and TSC autopsy cases. EPISTOP will be carried out by a consortium of 14 partners from 9 countries, including 2 SMEs.